The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Opioids for cancer pain - an overview of Cochrane reviews
Open accessAbstract
BACKGROUND: Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Opioid (morphine-like) drugs are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World Health Organization (WHO) pain treatment ladder. The most commonly-used opioid drugs are buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, tramadol, and tapentadol. OBJECTIVES: To provide an overview of the analgesic efficacy of opioids in cancer pain, and to report on adverse events associated with their use. METHODS: We identified systematic reviews examining any opioid for cancer pain published to 4 May 2017 in the Cochrane Database of Systematic Reviews in the Cochrane Library. The primary outcomes were no or mild pain within 14 days of starting treatment, withdrawals due to adverse events, and serious adverse events. MAIN RESULTS: We included nine reviews with 152 included studies and 13,524 participants, but because some studies appeared in more than one review the number of unique studies and participants was smaller than this. Most participants had moderate or severe pain associated with a range of different types of cancer. Studies in the reviews typically compared one type of opioid or formulation with either a different formulation of the same opioid, or a different opioid; few included a placebo control. Typically the reviews titrated dose to effect, a balance between pain relief and adverse events. Various routes of administration of opioids were considered in the reviews; oral with most opioids, but transdermal administration with fentanyl, and buprenorphine. No review included studies of subcutaneous opioid administration. Pain outcomes reported were varied and inconsistent. The average size of included studies varied considerably between reviews: studies of older opioids, such as codeine, morphine, and methadone, had low average study sizes while those involving newer drugs tended to have larger study sizes.Six reviews reported a GRADE assessment (buprenorphine, codeine, hydromorphone, methadone, oxycodone, and tramadol), but not necessarily for all comparisons or outcomes. No comparative analyses were possible because there was no consistent placebo or active control. Cohort outcomes for opioids are therefore reported, as absolute numbers or percentages, or both.Reviews on buprenorphine, codeine with or without paracetamol, hydromorphone, methadone, tramadol with or without paracetamol, tapentadol, and oxycodone did not have information about the primary outcome of mild or no pain at 14 days, although that on oxycodone indicated that average pain scores were within that range. Two reviews, on oral morphine and transdermal fentanyl, reported that 96% of 850 participants achieved that goal.Adverse event withdrawal was reported by five reviews, at rates of between 6% and 19%. Participants with at least one adverse event were reported by three reviews, at rates of between 11% and 77%.Our GRADE assessment of evidence quality was very low for all outcomes, because many studies in the reviews were at high risk of bias from several sources, including small study size. AUTHORS' CONCLUSIONS: The amount and quality of evidence around the use of opioids for treating cancer pain is disappointingly low, although the evidence we have indicates that around 19 out of 20 people with moderate or severe pain who are given opioids and can tolerate them should have that pain reduced to mild or no pain within 14 days. This accords with the clinical experience in treating many people with cancer pain, but overstates to some extent the effectiveness found for the WHO pain ladder. Most people will experience adverse events, and help may be needed to manage the more common undesirable adverse effects such as constipation and nausea. Perhaps between 1 in 10 and 2 in 10 people treated with opioids will find these adverse events intolerable, leading to a change in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Madadi, P., Koren, G., Cairns, J., Chitayat, D. A., Gaedigk, A., Leeder, J. S., Teitelbaum, R., Karaskov, T., & Aleksa, K. (2007) · PubMed · Cited by 165
RetractedCochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis
van den Beuken-van Everdingen, M. H. J., Hochstenbach, L. M. J., Joosten, E. A. J., Tjan-Heijnen, V. C. G., & Janssen, D. J. A. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.12.340 · Cited by 1,663
Publication bias in meta-analysis its causes and consequences
Thornton, A. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00161-4 · Cited by 1,291
Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70040-2 · Cited by 1,243
Portenoy, R. K., & Lesage, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01310-0 · Cited by 1,017
Song, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943
Brok, J., Thorlund, K., Wetterslev, J., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn188 · Cited by 917
Prevalence of undertreatment in cancer pain. A review of published literature
Deandrea, S., Montanari, M., Moja, L., & Apolone, G. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn419 · Cited by 870
GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes
Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.012 · Cited by 836
Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes
Breivik, H., Cherny, N., Collett, B., de Conno, F., Filbet, M., Foubert, A. J., Cohen, R., & Dow, L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp001 · Cited by 797
Morris, J. A., & Gardner, M. J. (1988) · BMJ · doi:10.1136/bmj.296.6632.1313 · Cited by 764
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
Indirect comparisons of competing interventions
Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D'Amico, R., Bradburn, M., & Eastwood, A. (2005) · Health Technology Assessment · doi:10.3310/hta9260 · Cited by 677
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews
Turner, R. M., Bird, S. M., & Higgins, J. P. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059202 · Cited by 672
Moore, A. R., Gavaghan, D., Tramèr, R. M., Collins, L. S., & McQuay, J. H. (1998) · Pain · doi:10.1016/s0304-3959(98)00140-7 · Cited by 604
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W. S., Tschannen, B., Altman, D. G., Egger, M., & Juni, P. (2010) · BMJ · doi:10.1136/bmj.c3515 · Cited by 559
Influence of trial sample size on treatment effect estimates: meta-epidemiological study
Dechartres, A., Trinquart, L., Boutron, I., & Ravaud, P. (2013) · BMJ · doi:10.1136/bmj.f2304 · Cited by 544
The WHO Analgesic Ladder for Cancer Pain Management: Stepping Up the Quality of Its Evaluation
Jadad, A. R. (1995) · JAMA · doi:10.1001/jama.1995.03530230056031 · Cited by 453
Management of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Bandieri, E., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr390 · Cited by 447
Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
Paul, D., Standifer, K. M., Inturrisi, C. E., & Pasternak, G. W. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20832-1 · Cited by 393
Andrew, R., Derry, S., Taylor, R. S., Straube, S., & Phillips, C. J. (2014) · Pain Practice · doi:10.1111/papr.12050 · Cited by 375
Self-citationMeta-assessment of bias in science
Fanelli, D., Costas, R., & Ioannidis, J. P. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618569114 · Cited by 364
Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome
Moore, R. A., Straube, S., & Aldington, D. (2013) · Anaesthesia · doi:10.1111/anae.12148 · Cited by 362
Self-citationManagement of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Santini, D., Maranzano, E., Berti, M., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds233 · Cited by 329
Thorlund, K., Imberger, G., Walsh, M., Chu, R., Gluud, C., Wetterslev, J., Guyatt, G., Devereaux, P. J., & Thabane, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025491 · Cited by 319
Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews
Moore, R. A., Derry, S., Aldington, D., & Wiffen, P. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008659.pub3 · Cited by 258
Self-citationChanges in trends and pattern of strong opioid prescribing in primary care
Zin, C. S., Chen, L. ‐., & Knaggs, R. D. (2014) · European Journal of Pain · doi:10.1002/j.1532-2149.2014.496.x · Cited by 241
Association Between Analytic Strategy and Estimates of Treatment Outcomes in Meta-analyses
Dechartres, A., Altman, D. G., Trinquart, L., Boutron, I., & Ravaud, P. (2014) · JAMA · doi:10.1001/jama.2014.8166 · Cited by 233
Management of cancer pain: ESMO Clinical Practice Guidelines
Jost, L., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq224 · Cited by 225
Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication
Cascorbi, I. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.3.x · Cited by 206
Nicholson, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003971.pub2 · Cited by 189
Azevedo São Leão Ferreira, K., Kimura, M., & Jacobsen Teixeira, M. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0086-x · Cited by 182
Wiffen, P. J., Wee, B., & Moore, R. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003868.pub3 · Cited by 180
Self-citationEffectiveness of the World Health Organization Cancer Pain Relief Guidelines: an integrative review
Carlson, C. (2016) · Journal of Pain Research · doi:10.2147/jpr.s97759 · Cited by 171
Systematic review of factors affecting the ratios of morphine and its major metabolites
Faura, C. C., Collins, S. L., Moore, A. R., & McQuay, H. J. (1998) · Pain · doi:10.1016/s0304-3959(97)00142-5 · Cited by 165
Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults
Derry, S., Wiffen, P. J., Moore, A., McNicol, E. D., Bell, R. F., Carr, D. B., McIntyre, M., & Wee, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012638.pub2 · Cited by 150
Self-citationWiffen, P. J., & McQuay, H. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003868.pub2 · Cited by 146
Self-citationThe knowledge system underpinning healthcare is not fit for purpose and must change
Roberts, I., Ker, K., Edwards, P. J., Beecher, D., Manno, D., & Sydenham, E. (2015) · BMJ · doi:10.1136/bmj.h2463 · Cited by 135
Wiffen, P. J., Wee, B., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003868.pub4 · Cited by 129
Self-citationSear, J. W., Hand, C. W., Moore, A., & McQuay, H. (1989) · British Journal of Anaesthesia · doi:10.1093/bja/62.1.28 · Cited by 125
Oral paracetamol (acetaminophen) for cancer pain
Wiffen, P. J., Derry, S., Moore, A., McNicol, E. D., Bell, R. F., Carr, D. B., McIntyre, M., & Wee, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012637.pub2 · Cited by 118
Self-citationPeak Plasma Concentrations After Oral Morphine
Collins, S., Faura, C. C., Moore, R. A., & McQuay, H. J. (1998) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(98)00094-3 · Cited by 109
Self-citationOxycodone for cancer-related pain
Schmidt‐Hansen, M., Bennett, M., Arnold, S. J., Bromham, N., & Hilgart, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003870.pub6 · Cited by 108
Moore, R. A., Derry, S., McQuay, H. J., Straube, S., Aldington, D., Wiffen, P., Bell, R. F., Kalso, E., & Rowbotham, M. C. (2010) · Pain · doi:10.1016/j.pain.2009.08.007 · Cited by 98
Self-citationTransdermal fentanyl for cancer pain
Hadley, G., Derry, S., Moore, R. A., & Wiffen, P. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010270.pub2 · Cited by 92
Self-citationStatistics with confidence—Confidence intervals and statistical guidelines
Wastell, D. G. (1991) · Journal of Dentistry · doi:10.1016/0300-5712(91)90131-h · Cited by 90
Buprenorphine for treating cancer pain
Schmidt‐Hansen, M., Bromham, N., Taubert, M., Arnold, S. J., & Hilgart, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009596.pub4 · Cited by 87
Tramadol with or without paracetamol (acetaminophen) for cancer pain
Wiffen, P. J., Derry, S., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012508.pub2 · Cited by 79
Self-citationSimple randomization did not protect against bias in smaller trials
Nguyen, T., Collins, P. G. S., Lamy, A. L., Devereaux, P. J., Daurès, J., Landais, P., & Manach, Y. L. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.02.010 · Cited by 77
Codeine, alone and with paracetamol (acetaminophen), for cancer pain
Straube, C., Derry, S., Jackson, K. C., Wiffen, P. J., Bell, R. F., Strassels, S. A., & Straube, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006601.pub4 · Cited by 75
Self-citationOpioids for cancer-related pain in children and adolescents
Wiffen, P. J., Cooper, T. E., Anderson, A.-K., Gray, A. L., Grégoire, M.-C., Ljungman, G., & Zernikow, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012564.pub2 · Cited by 75
Self-citationWiffen, P. J., Derry, S., & Moore, R. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011056.pub2 · Cited by 71
Self-citationBao, Y. J., Hou, W., Kong, X. Y., Yang, L., Xia, J., Hua, B., & Knaggs, R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011108.pub2 · Cited by 65
Oxycodone for cancer-related pain
Schmidt‐Hansen, M., Bennett, M., Arnold, S. J., Bromham, N., & Hilgart, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003870.pub5 · Cited by 62
Deng, D., Fu, L., Zhao, Y. X., Wu, X., Zhang, G., Chen, L., Xie, C. H., & Zhou, Y. (2011) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111418636 · Cited by 60
on behalf of the IOPS MS study Group, Mercadante, S., Marchetti, P., Cuomo, A., Mammucari, M., & Caraceni, A. T. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2951-y · Cited by 58
Pharmacological Management of Cancer-Related Pain
Prommer, E. (2015) · Cancer Control · doi:10.1177/107327481502200407 · Cited by 57
Oral tapentadol for cancer pain
Wiffen, P. J., Derry, S., Naessens, K., & Bell, R. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011460.pub2 · Cited by 53
Self-citationOral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults
Derry, S., Wiffen, P. J., Moore, R. A., McNicol, E. D., Bell, R. F., Carr, D. B., McIntyre, M., & Wee, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012638 · Cited by 47
Self-citationOral paracetamol (acetaminophen) for cancer pain
Wiffen, P. J., Derry, S., Moore, R. A., McNicol, E. D., Bell, R. F., Carr, D. B., McIntyre, M., & Wee, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012637 · Cited by 45
Self-citationPain, Sleep Disturbance, and Quality of Life Among Palestinian Patients Diagnosed with Cancer
Dreidi, M. M., & Hamdan‐Mansour, A. M. (2015) · Journal of Cancer Education · doi:10.1007/s13187-015-0946-5 · Cited by 38
Albalawi, Z., McAlister, F. A., Thorlund, K., Wong, M. M., & Wetterslev, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.11.048 · Cited by 37
Ripamonti, C. I. (2012) · Annals of Oncology · doi:10.1093/annonc/mds360 · Cited by 36
Tramadol with or without paracetamol (acetaminophen) for cancer pain
Wiffen, P. J., Derry, S., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012508 · Cited by 36
Self-citationOpioids for cancer-related pain in children and adolescents
Wiffen, P. J., Cooper, T. E., Anderson, A.-K., Gray, A. L., Grégoire, M.-C., Ljungman, G., & Zernikow, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012564 · Cited by 29
Self-citationMikan, F., Wada, M., Yamada, M., Takahashi, A., Onishi, H., Ishida, M., Sato, K., Shimizu, S., Matoba, M., & Miyashita, M. (2016) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909116630266 · Cited by 25
Cited by
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
Henson, L. A., Maddocks, M., Evans, C., Davidson, M., Hicks, S., & Higginson, I. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00470 · Cited by 367
A systematic review: mindfulness intervention for cancer-related pain
Ngamkham, S., Holden, J. E., & Smith, E. L. (2019) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_67_18 · Cited by 103
“Globally, between 30% and 50% of the approximately 32 million people living with cancer([1]) experience moderate‐to‐severe pain.”
BackgroundZobdeh, F., Eremenko, I. I., Akan, M. A., Tarasov, V. V., Chubarev, V. N., Schiöth, H. B., & Mwinyi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061190 · Cited by 45
Bidonde, J., Fisher, E., Perrot, S., Moore, R. A., Bell, R. F., Makri, S., & Häuser, W. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152248 · Cited by 27
Self-citation
Metadata
- Authors
- Wiffen, P. J., Wee, B., Derry, S., Bell, R. F., & Moore, R. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-07-06
- Volume
- 2020
- Issue
- 2
- Pages
- CD012592-CD012592
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2592597011
- Cited by
- 271
- References
- 71
- FWCI
- 30.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.